REG - Sareum Holdings PLC - Update on SDC-1801 Clinical Trial Progress

Sareum HoldingsAnnouncement

15/02/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240215:nRSO1834Da&default-theme=true

RNS Number : 1834D  Sareum Holdings PLC  15 February 2024

 Sareum Holdings PLC

("Sareum" or the "Company")

Update on SDC-1801 Clinical Trial Progress

-      Sareum completes dosing in the single ascending dose (SAD) part
and the food effect study of Phase 1a clinical trial for SDC-1801

 

-      Preliminary results indicate the potential of SDC-1801 to achieve
therapeutically effective dose levels with no serious adverse events

Cambridge, UK, 15 February 2024 - Sareum Holdings plc (AIM: SAR), a
clinical-stage biotechnology company developing next generation kinase
inhibitors for autoimmune disease and cancer, today announces the completion
of the single ascending dose (SAD) part and the food effect study of its Phase
1a clinical trial for the lead programme SDC-1801.

SDC-1801 is a dual TYK2/JAK1 kinase inhibitor being developed as a potential
new therapeutic for a range of autoimmune diseases with an initial focus on
psoriasis, an autoimmune condition affecting the skin.

The Phase 1a trial is designed to investigate the safety, tolerability,
pharmacokinetics and pharmacodynamics of an oral formulation of SDC-1801 in
healthy subjects (trial ID ACTRN12623000416695p). This is a randomised,
placebo-controlled trial with single and multiple ascending oral dose studies.
This trial includes a single ascending dose study (Part 1), a multiple
ascending dose study (Part 2) and a food effects study (Part 3).

Dosing of the final subjects in the SAD part of the trial has now concluded
and the safety review committee for the trial has reviewed available data. The
SAD study randomised participants in a 3:1 ratio to a single dose of SDC-1801
or placebo in six dose cohorts. Preliminary blinded safety, tolerability and
pharmacokinetics data from the trial indicate a favourable profile and support
oral dosing of patients once daily. These preliminary results indicate that
SDC-1801 has the potential to achieve therapeutically effective dose levels
with no serious adverse events.

The food effect study part of the trial has also been completed. The results
of this study demonstrated no significant food effect on SDC-1801 blood
levels, which will allow full flexibility in dose timing in future clinical
studies.

The multiple ascending dose study is ongoing and full safety data from the
Phase 1a clinical trial are expected to be available during the first half of
2024. If the results are satisfactory and subject to financing, regulatory
requirements, and recruitment preparations, the Company plans to initiate a
Phase 1b clinical study. The goal is to recruit up to 24 psoriasis patients,
with the study expected to be completed by the end of 2024.

Dr Tim Mitchell, CEO of Sareum, commented: "We're pleased to announce that
Sareum has cleared an important milestone in this trial. We are encouraged by
the preliminary data from the SAD and food effect parts of the Phase 1a trial
for SDC-1801, which support our confidence in the trial and the broader
clinical strategy.

"These are preliminary results but if we continue to see the positive safety
profile and pharmacokinetic data we have seen so far, this will underpin our
planning for the Phase 1b part of the study and beyond. We look forward to the
data from the multiple ascending dose part of this trial, which will help us
advance towards this critical next point in the study."

 

-Ends-

For further information, please contact:

 Sareum Holdings plc

 Tim Mitchell, CEO                                01223 497700

 Lauren Williams, Head of Investor Relations      ir@sareum.co.uk

 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                      020 7409 3494

 Peel Hunt LLP (Joint Corporate Broker)

 James Steel / Patrick Birkholm                   020 7418 8900

 Hybridan LLP (Joint Corporate Broker)

 Claire Noyce                                     020 3764 2341

 ICR Consilium (Financial PR)

 Jessica Hodgson / Davide Salvi / Kumail Waljee   020 3709 5700

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulation
(EU) No. 596/2014 as it forms part of United Kingdom domestic law by virtue of
the European Union (Withdrawal) Act 2018, as amended by virtue of the Market
Abuse (Amendment) (EU Exit) Regulations 2019 ("UK MAR").

About Sareum

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing
next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which
modify the activity of the JAK kinase family and have best-in-class potential.
Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801
is a potential treatment for a range of autoimmune diseases and has entered
Phase 1a/b clinical development with an initial focus on psoriasis.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential
application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market
of the London Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at www.sareum.com
(about:blank)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDQKQBBOBKDKBD